Omega Therapeutics Inc Cash Flow Conversion Efficiency
Omega Therapeutics Inc cash flow conversion efficiency. Based on the latest financial reports, Omega Therapeutics Inc (OMGA) has a cash flow conversion efficiency ratio of -1.214x as of September 2024. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-14.02 Million) by net assets ($11.54 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Omega Therapeutics Inc (2019–2023)
Cash flow conversion efficiency of Omega Therapeutics Inc from 2019 to 2023. This chart illustrates how Omega Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View latest Omega Therapeutics Inc stock price today for real-time trading data and today's change.
Omega Therapeutics Inc Cash Flow Conversion Ratio Explained
Omega Therapeutics Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Omega Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Omega Therapeutics Inc ranked by their cash flow conversion efficiency. Also see Omega Therapeutics Inc (OMGA) market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Smooth Rock Ventures Corp
V:SMRV
|
-0.028x |
|
NORTHERN SHIELD RES INC.
F:N9SA
|
N/A |
|
Butn Ltd
AU:BTN
|
0.098x |
|
Viver Incorporadora e Construtora S.A
SA:VIVR3
|
-2.045x |
|
Calidi Biotherapeutics Inc.
NYSE MKT:CLDI
|
-1.342x |
|
Rakovina Therapeutics Inc
V:RKV
|
-0.548x |
|
Sylvania Platinum Limited
LSE:SLP
|
0.095x |
|
Empire Metals Limited
LSE:EEE
|
-0.098x |
Annual Cash Flow Conversion Efficiency for Omega Therapeutics Inc (2019–2023)
The table below shows the annual cash flow conversion efficiency of Omega Therapeutics Inc from 2019 to 2023. Review financial flexibility index of Omega Therapeutics Inc to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2023-12-31 | $58.02 Million | $-91.51 Million | -1.577x | -69.67% |
| 2022-12-31 | $105.97 Million | $-98.52 Million | -0.930x | -223.76% |
| 2021-12-31 | $200.63 Million | $-57.61 Million | -0.287x | -171.01% |
| 2020-12-31 | $-64.63 Million | $-26.13 Million | 0.404x | -7.37% |
| 2019-12-31 | $-35.92 Million | $-15.68 Million | 0.437x | -- |
About Omega Therapeutics Inc
Omega Therapeutics, Inc. operates as a clinical-stage biotechnology company. The company's OMEGA platform enables control of fundamental epigenetic processes to correct the root cause of disease by restoring aberrant gene expression to a range without altering native nucleic acid sequences. It also develops OTX-2002 for hepatocellular carcinoma; OTX-2101 for non-small cell lung cancer; omega epig… Read more